| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/02/2009 | CA2698762A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | CA2698751A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698673A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698672A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2697629A1 Molecular delivery vesicle |
| 04/02/2009 | CA2697583A1 Antidotes for factor xa inhibitors and methods of using the same |
| 04/02/2009 | CA2696113A1 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 04/01/2009 | EP2042606A1 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use |
| 04/01/2009 | EP2042598A1 5T4 tumour-associated antigen for use in tumour immunotherapy |
| 04/01/2009 | EP2042597A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 04/01/2009 | EP2042596A1 Polypeptides involved in immune response |
| 04/01/2009 | EP2042591A1 Erythropoietin-producing organoid precursor, method of constructing the same and method of treating erythropoietin-related disease |
| 04/01/2009 | EP2042513A1 Galectin 9-polymer conjugate |
| 04/01/2009 | EP2042512A2 Polynucleic acids and proteins from a porcine reproductive and respiratory syndrome virus and uses thereof |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042509A1 Modulators of the function of FAS receptors and other proteins |
| 04/01/2009 | EP2042196A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 04/01/2009 | EP2042192A2 Tolerogenic fragments of natural allergens |
| 04/01/2009 | EP2042190A1 Ameliorating agent for brain damage |
| 04/01/2009 | EP2042189A1 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof |
| 04/01/2009 | EP2042188A1 Pharmaceutical composition for treating or preventing hcv infection |
| 04/01/2009 | EP2042187A1 Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 04/01/2009 | EP2042186A1 Novel polypeptide ligands for toll-like receptor 2 (TLR2) |
| 04/01/2009 | EP2042166A1 Nanocapsules for oral delivery of proteins |
| 04/01/2009 | EP2042161A1 Propellant-free spray composition comprising anti-emetic agent |
| 04/01/2009 | EP2042157A1 Hair growth composition |
| 04/01/2009 | EP2041338A1 Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects |
| 04/01/2009 | EP2041282A2 Sdf-i binding nucleic acids |
| 04/01/2009 | EP2041173A2 Peptides with anti-proliferative activity |
| 04/01/2009 | EP2041171A2 Epitope-tag for surface-expressed proteins and uses thereof |
| 04/01/2009 | EP2041168A2 Novel analogs of vasoactive intestinal peptide |
| 04/01/2009 | EP2041161A1 Chiral compounds substituted with phosphonate ester or phosphonic acid |
| 04/01/2009 | EP2041160A2 Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| 04/01/2009 | EP2041159A1 Macrocyclic compounds as antiviral agents |
| 04/01/2009 | EP2041158A2 Peptide epoxyketones for proteasome inhibition |
| 04/01/2009 | EP2041157A1 Peptide derivatives with therapeutic activity |
| 04/01/2009 | EP2041156A1 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| 04/01/2009 | EP2040801A1 Method for reducing spasms comprising treatment with an agent that elevates the level of one or more cyclic nucleotides in the muscle |
| 04/01/2009 | EP2040741A1 Hyaluronic acid and hyaluronidase in the enhancement of lens regeneration |
| 04/01/2009 | EP2040739A2 Use of inducer of promyelocytic leukemia protein (pml) for treating polyglutamine expansion neurodegenerative diseases |
| 04/01/2009 | EP2040738A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 04/01/2009 | EP2040737A1 Epidermal growth factor increasing insulin secretion and lowering blood glucose |
| 04/01/2009 | EP2040736A1 New formulation for increasing bioavailability of neurturin |
| 04/01/2009 | EP2040735A2 Cationic milk proteins for treating mastitis |
| 04/01/2009 | EP2040734A2 Antisecretory protein for use in the treatment of compartment syndrome |
| 04/01/2009 | EP2040733A2 Method for elevating prolactin in mammals |
| 04/01/2009 | EP2040732A1 New use of therapeutically useful peptides |
| 04/01/2009 | EP2040731A2 Solid oral dosage form containing an enhancer |
| 04/01/2009 | EP2040730A2 Modulation of nkg2d |
| 04/01/2009 | EP2040729A2 Attenuation of reperfusion injury |
| 04/01/2009 | EP2040728A2 Fkbp-l and uses thereof |
| 04/01/2009 | EP2040689A2 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
| 04/01/2009 | EP1939216A4 Immunomodulating composition |
| 04/01/2009 | EP1917032B1 Use of a botulinum toxin to improve gastric emptying and/or to treat gerd |
| 04/01/2009 | EP1879612B1 Use of native peptides and their optimized derivatives for vaccination |
| 04/01/2009 | EP1835926A4 Plasmin-inhibitory therapies |
| 04/01/2009 | EP1824874B1 A processs for the purification of crude vancomycin |
| 04/01/2009 | EP1721616B1 Protein hydrolysate for treating fatigue |
| 04/01/2009 | EP1718325B1 Treatment of bacterial infections |
| 04/01/2009 | EP1629098B1 Complement inhibitors from ticks |
| 04/01/2009 | EP1572241B1 Oral pharmaceutical compositions comprising cyclosporin |
| 04/01/2009 | EP1549341B1 Tissue factor targeted antibodies as anticoagulants |
| 04/01/2009 | EP1532248B1 Modified small interfering rna molecules and methods of use |
| 04/01/2009 | EP1472375B1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 04/01/2009 | EP1456239B1 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 04/01/2009 | EP1446425B1 Treatment of micro-organism infection |
| 04/01/2009 | EP1425582B1 Diagnostic markers for ischemia and risk of mortaility |
| 04/01/2009 | EP1368486A4 Formulations for il-11 |
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1137666B9 Glp-1 analogues |
| 04/01/2009 | EP1131087B2 Alleviatation of prostate cancer symptoms |
| 04/01/2009 | EP1119623B1 Mage-a3 peptides presented by hla class ii molecules |
| 04/01/2009 | EP0970207B1 Heregulin variants |
| 04/01/2009 | EP0888386B2 Stable, virus-safe factor VIII-complex concentrate |
| 04/01/2009 | EP0847452B1 Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion |
| 04/01/2009 | CN101400790A Peptide for inhibition of influenza infection, inhibitor of influenza infection, liposome, and prophylactic/therapeutic agent for influenza |
| 04/01/2009 | CN101400787A Mass producing method of growth factor using adipose derived adult stem cells |
| 04/01/2009 | CN101400693A Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof |
| 04/01/2009 | CN101400692A Potent compstatin analogs |
| 04/01/2009 | CN101400691A Tropolone- and hydroxybenzene-substituted oligopeptides for depigmentation |
| 04/01/2009 | CN101400367A Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist |
| 04/01/2009 | CN101400365A Use of TFPI to treat severe bacterial infections |
| 04/01/2009 | CN101400364A Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides |
| 04/01/2009 | CN101400363A Pharmaceutical compositions with enhanced stability |
| 04/01/2009 | CN101400362A Bifunctional histone deacetylase inhibitors |
| 04/01/2009 | CN101400361A Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| 04/01/2009 | CN101400356A Treatment of acute respiratory distress syndrome |
| 04/01/2009 | CN101400338A Pharmaceutical composition of microspheres for preventing diabetic foot amputation |
| 04/01/2009 | CN101400337A Method for solubilizing, dispersing, and stabilizing materials, products manufactured according to said method, and use thereof |
| 04/01/2009 | CN101397566A Superoxide dismutase and coding gene thereof |
| 04/01/2009 | CN101397564A Protection against environmental toxicity through manipulation of the processing of messenger RNA precursors |
| 04/01/2009 | CN101397551A Neukinase and its use in treatment of cardiovascular disease |
| 04/01/2009 | CN101397343A VEGF receptor fusion protein and its use in preparation of medicament for treating eye disease |
| 04/01/2009 | CN101397339A Method for removing/inactivating virus in glucoprotein |
| 04/01/2009 | CN101397337A Neuroregulation protein mutant and uses thereof |
| 04/01/2009 | CN101397336A Antigenic Neisserial peptides |
| 04/01/2009 | CN101397333A De-hydroxyl vancomycin, preparation method thereof, medicament composition and use thereof |
| 04/01/2009 | CN101397331A Enzyme inhibitors, preparation method and use thereof |
| 04/01/2009 | CN101396563A Chitose derivates using octreotide as target ligand and use thereof in medicament |
| 04/01/2009 | CN101396555A Methods and compositions for interferon therapy |